THE SMART TRICK OF TRASTUZUMAB DRUG CLASS THAT NO ONE IS DISCUSSING

One of the most less than-investigated “driving forces” associated with trastuzumab resistance is PTEN. Nagata et al. (2004) noted which the lack of PTEN was observed in 36% of HER2-beneficial Major breast tumor specimens from people with stage IV ailment. Furthermore, Additionally they confirmed that patients with PTEN-deficient tumors had rem